Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

ClinicalTrials.gov ID: NCT04560569

Public ClinicalTrials.gov record NCT04560569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.

Study identification

NCT ID
NCT04560569
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Enrollment
20 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 29, 2021
Primary completion
Oct 31, 2022
Completion
Nov 30, 2022
Last update posted
Sep 28, 2021

2021 – 2022

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
ABT-3BNC117_203 Investigational Site Canoga Park California 91309 Recruiting
ABT-3BNC117_203 Investigational Site San Francisco California 94115 Recruiting
ABT-3BNC117_203 Investigational Site Hialeah Florida 33016 Recruiting
ABT-3BNC117_203 Investigational Site Orlando Florida 32803 Recruiting
ABT-3BNC117_203 Investigational Site West Palm Beach Florida 33407 Recruiting
ABT-3BNC117_203 Investigational Site Decatur Georgia 30030 Recruiting
ABT-3BNC117_203 Investigational Site St Louis Missouri 63108 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04560569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 28, 2021 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04560569 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →